Cargando…
In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928
Streptococcosis is recognized as a leading infectious disease in the swine industry. Streptococcus suis serotype 2 is regarded as the most virulent species, which threatens human and pig health and causes serious economic losses. In this study, multiple in vitro and in vivo effects of MP1102 on mult...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399382/ https://www.ncbi.nlm.nih.gov/pubmed/30863725 http://dx.doi.org/10.3389/fcimb.2019.00048 |
_version_ | 1783399750031114240 |
---|---|
author | Zhao, Fei Yang, Na Wang, Xiumin Mao, Ruoyu Hao, Ya Li, Zhanzhan Wang, Xiao Teng, Da Fan, Huan Wang, Jianhua |
author_facet | Zhao, Fei Yang, Na Wang, Xiumin Mao, Ruoyu Hao, Ya Li, Zhanzhan Wang, Xiao Teng, Da Fan, Huan Wang, Jianhua |
author_sort | Zhao, Fei |
collection | PubMed |
description | Streptococcosis is recognized as a leading infectious disease in the swine industry. Streptococcus suis serotype 2 is regarded as the most virulent species, which threatens human and pig health and causes serious economic losses. In this study, multiple in vitro and in vivo effects of MP1102 on multidrug resistant S. suis was studied for the first time. MP1102 exhibited significant antibacterial activity against S. suis (minimum inhibitory concentration, MIC = 0.028–0.228 μM), rapid bacteriocidal action, a longer postantibiotic effect than ceftriaxone, and a synergistic or additive effect with lincomycin, penicillin, and ceftriaxone (FICI = 0.29–0.96). No resistant mutants appeared after 30 serial passages of S. suis in the presence of MP1102. Flow cytometric analysis and electron microscopy observations showed that MP1102 destroyed S. suis cell membrane integrity and affected S. suis cell ultrastructure and membrane morphology. Specifically, a significantly wrinkled surface, intracellular content leakage, and cell lysis were noted, establishing a cyto-basis of nonresistance to this pathogen. DNA gel retardation and circular dichroism analysis indicated that MP1102 interacted with DNA by binding to DNA and changing the DNA conformation, even leading to the disappearance of the helical structure. This result further supported the mechanistic basis of nonresistance via interaction with an intracellular target, which could serve as a means of secondary injury after MP1102 is transported across the membrane. Upon treatment with 2.5–5.0 mg/kg MP1102, the survival of mice challenged with S. suis was 83.3–100%. MP1102 decreased bacterial translocation in liver, lung, spleen, and blood; inhibited the release of interleukin-1β and tumor necrosis factor-α; and relieved the lung, liver, and spleen from acute injury induced by S. suis. These results suggest that MP1102 is a potent novel antibacterial agent for the treatment of porcine streptococcal disease. |
format | Online Article Text |
id | pubmed-6399382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63993822019-03-12 In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 Zhao, Fei Yang, Na Wang, Xiumin Mao, Ruoyu Hao, Ya Li, Zhanzhan Wang, Xiao Teng, Da Fan, Huan Wang, Jianhua Front Cell Infect Microbiol Cellular and Infection Microbiology Streptococcosis is recognized as a leading infectious disease in the swine industry. Streptococcus suis serotype 2 is regarded as the most virulent species, which threatens human and pig health and causes serious economic losses. In this study, multiple in vitro and in vivo effects of MP1102 on multidrug resistant S. suis was studied for the first time. MP1102 exhibited significant antibacterial activity against S. suis (minimum inhibitory concentration, MIC = 0.028–0.228 μM), rapid bacteriocidal action, a longer postantibiotic effect than ceftriaxone, and a synergistic or additive effect with lincomycin, penicillin, and ceftriaxone (FICI = 0.29–0.96). No resistant mutants appeared after 30 serial passages of S. suis in the presence of MP1102. Flow cytometric analysis and electron microscopy observations showed that MP1102 destroyed S. suis cell membrane integrity and affected S. suis cell ultrastructure and membrane morphology. Specifically, a significantly wrinkled surface, intracellular content leakage, and cell lysis were noted, establishing a cyto-basis of nonresistance to this pathogen. DNA gel retardation and circular dichroism analysis indicated that MP1102 interacted with DNA by binding to DNA and changing the DNA conformation, even leading to the disappearance of the helical structure. This result further supported the mechanistic basis of nonresistance via interaction with an intracellular target, which could serve as a means of secondary injury after MP1102 is transported across the membrane. Upon treatment with 2.5–5.0 mg/kg MP1102, the survival of mice challenged with S. suis was 83.3–100%. MP1102 decreased bacterial translocation in liver, lung, spleen, and blood; inhibited the release of interleukin-1β and tumor necrosis factor-α; and relieved the lung, liver, and spleen from acute injury induced by S. suis. These results suggest that MP1102 is a potent novel antibacterial agent for the treatment of porcine streptococcal disease. Frontiers Media S.A. 2019-02-26 /pmc/articles/PMC6399382/ /pubmed/30863725 http://dx.doi.org/10.3389/fcimb.2019.00048 Text en Copyright © 2019 Zhao, Yang, Wang, Mao, Hao, Li, Wang, Teng, Fan and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Zhao, Fei Yang, Na Wang, Xiumin Mao, Ruoyu Hao, Ya Li, Zhanzhan Wang, Xiao Teng, Da Fan, Huan Wang, Jianhua In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 |
title | In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 |
title_full | In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 |
title_fullStr | In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 |
title_full_unstemmed | In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 |
title_short | In vitro/vivo Mechanism of Action of MP1102 With Low/Nonresistance Against Streptococcus suis Type 2 Strain CVCC 3928 |
title_sort | in vitro/vivo mechanism of action of mp1102 with low/nonresistance against streptococcus suis type 2 strain cvcc 3928 |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399382/ https://www.ncbi.nlm.nih.gov/pubmed/30863725 http://dx.doi.org/10.3389/fcimb.2019.00048 |
work_keys_str_mv | AT zhaofei invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT yangna invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT wangxiumin invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT maoruoyu invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT haoya invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT lizhanzhan invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT wangxiao invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT tengda invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT fanhuan invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 AT wangjianhua invitrovivomechanismofactionofmp1102withlownonresistanceagainststreptococcussuistype2straincvcc3928 |